Clinical stage biopharmaceutical company Trevi Therapeutics Inc (NASDAQ:TRVI) could be the stock to track this morning considering the fact that it has made a big move in the premarket trading period and gone up by as much as 32%.
In this regard, it should be point out that the action in the stock is possibly related to an announcement that had been made by the company back on October 7. The company announced that members from its senior management were going to be involved in one on one virtual meetings at the Alliance Global Partners’ Virtual Biotech & Specialty Pharma Conference which is going to be held on October 13, 2021.
It goes without saying that the participation in conference of this nature can often lead to greater publicity for a company and its work. Thereby leading to more exposure to potential investors and hence, the rally in the Trevi stock is perhaps understandable. The company is currently involved in developing and commercialising its therapy named Haduvio.
It is meant for the treatment of neurologically mediate conditions which are of a serious nature. At this point the company is engaged in conducting a Phase 2b/3 trial of the treatment.
